Author

Lupe Duarte

Observed name: L Duarte

Observed institutions: City Of Hope National Medical Center, City of Hope

OpenAlex ID: A5046080795

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

2018 · Amrita Krishnan, Prashant Kapoor, et al. · Leukemia · 51

Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study

2020 · Michael Rosenzweig, Joycelynne Palmer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma

2015 · Shaji K Kumar, Amrita Krishnan, et al. · American Journal of Hematology · 22

PDF

Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma

2011 · Firoozeh Sahebi, Paul H. Frankel, et al. · Transplantation and Cellular Therapy · 18

A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.

2016 · Amrita Y. Krishnan, Prashant Kapoor, et al. · Journal of Clinical Oncology · 11

A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

2024 · Ryotaro Nakamura, Corinna La Rosa, et al. · Haematologica · 9

PDF

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

2017 · A Krishnan, P Kapoor, et al. · Leukemia · 9

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

2016 · Amrita Krishnan, Prashant Kapoor, et al. · Blood · 9

First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL).

2008 · Amrita Krishnan, John A. Zaia, et al. · Blood · 5

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

2021 · Ryotaro Nakamura, Corinna La Rosa, et al. · Blood · 3

The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.

2010 · Sandra Wear, Paul G. Richardson, et al. · Blood · 2

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

2017 · Michael Rosenzweig, Joycelynne Palmer, et al. · Blood · 1

Incidence and Timing of Graft Versus Host Disease (GVHD) After Daratumumab(Dara) Anti CD38 Therapy Post Allogeneic Transplant (alloHCT)for Myeloma

2017 · Amrita Krishnan, Hari Parameswaran, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

NK Cell Recovery and Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

2013 · Myo Htut, Ghislaine Gallez-hawkins, et al. · Transplantation and Cellular Therapy · 1

PDF

A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.

2009 · Firoozeh Sahebi, Amrita Krishnan, et al. · Blood · 1

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

2018 · Michael Rosenzweig, Joycelynne Palmer, et al. · Blood

Costimulatory molecule profiles and NK cell recovery after autologous hematopoietic cell transplantation (HCT) in multiple myeloma (MM) patients.

2012 · Myo Htut, Ghislaine Gallez-Hawkins, et al. · Journal of Clinical Oncology

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

2011 · Sandra M. Wear, Paul G. Richardson, et al. · Blood

Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

2011 · Myo Htut, Ghislaine Gallez-Hawkins, et al. · Blood

Works count: 19

Citation count: 169

H-index: 8

I10-index: 5